Ang-（1—7）在急性呼吸窘迫综合征中的肺保护作用  

Recent advances of Angiotensin-（1-7） for the treatment of acute respiratory distress syndrome

作　　者：刘田[1] 陈秋华[1] 董亮[1] 邱海波[1] 

机构地区：[1]东南大学附属中大医院ICU,南京210009

出　　处：《国际呼吸杂志》2010年第23期1463-1466,共4页International Journal of Respiration

摘　　要：肺组织局部的肾素一血管紧张素系统（RAS）与急性呼吸窘迫综合征（ARDS）关系密切，血管紧张素Ⅱ（AngⅡ）通过其1型受体激活肺部炎症反应，促进ARDS发生发展。血管紧张素（1—7）Ang-（1-7）]也是RAS中得重要重要组分之一，能拮抗AngⅡ的生物学作用，被认为是AngⅡ的内源性拮抗剂。在ARDS中，Ang-（1-7）可能通过抑制炎症反应、减轻肺组织纤维化以及抗肺动脉高压等途径发挥肺保护作用，在ARDS中具有广阔的应用前景。It has been demonstrated that renin angiotensin system （RAS）was involved in the pathogenesis of acute respiratory distress syndrome （ARDS）. Angiotensin Ⅱ（Ang Ⅱ ）, which is the main effector of RAS, cotdd activate pulmonary inflammation through its receptor ATIR in ARDS. While recent findings has suggested that Angtensin （1-7）fAng （1-7）] ,the endougenous antagonist of Ang Ⅱ in RAS, could counter-regulate some pathological changes of Ang Ⅱ such as inflammation, fibrosis and pulmonary hypertension. These results indicate that Ang-（1-7） may protect from ARDS. In this review, we will focus on the recent findings related to the potential beneficial aspects of Ang-（1-7） in ARDS.

关 键 词：血管紧张素转化酶2 血管紧张素(1—7) MAS受体 急性呼吸窘迫综合征 

分 类 号：R563.8[医药卫生—呼吸系统]